These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24145531)

  • 1. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.
    Ng JK; Schulz LT; Rose WE; Fox BC; Andes DR; Buhr KA; Fish JT
    Antimicrob Agents Chemother; 2014; 58(1):88-93. PubMed ID: 24145531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States.
    Bookstaver PB; Bland CM; Qureshi ZP; Faulkner-Fennell CM; Sheldon MA; Caulder CR; Hartis C;
    Pharmacotherapy; 2013 Dec; 33(12):1322-30. PubMed ID: 23712701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with daptomycin in Europe: the first 2.5 years.
    Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Seaton RA; Loeffler J; Chaves RL
    J Antimicrob Chemother; 2011 Apr; 66(4):912-9. PubMed ID: 21393205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
    Martone WJ; Lamp KC
    Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin: rationale and role in the management of skin and soft tissue infections.
    Seaton RA
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.
    Jobson S; Moise PA; Eskandarian R
    Clin Ther; 2011 Oct; 33(10):1391-9. PubMed ID: 22015328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
    Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA
    Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.
    Seaton RA; Menichetti F; Dalekos G; Beiras-Fernandez A; Nacinovich F; Pathan R; Hamed K
    Adv Ther; 2015 Dec; 32(12):1192-205. PubMed ID: 26610384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
    Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
    Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial.
    Konychev A; Heep M; Moritz RK; Kreuter A; Shulutko A; Fierlbeck G; Bouylout K; Pathan R; Trostmann U; Chaves RL
    Drugs Aging; 2013 Oct; 30(10):829-36. PubMed ID: 23990341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.
    Britt NS; Potter EM; Patel N; Steed ME
    Clin Infect Dis; 2017 Mar; 64(5):605-613. PubMed ID: 28011602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.
    Crompton JA; North DS; Yoon M; Steenbergen JN; Lamp KC; Forrest GN
    J Antimicrob Chemother; 2010 Aug; 65(8):1784-91. PubMed ID: 20554570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose daptomycin in documented Staphylococcus aureus infections.
    Bassetti M; Nicco E; Ginocchio F; Ansaldi F; de Florentiis D; Viscoli C
    Int J Antimicrob Agents; 2010 Nov; 36(5):459-61. PubMed ID: 20846832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
    Kullar R; Casapao AM; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    J Antimicrob Chemother; 2013 Dec; 68(12):2921-6. PubMed ID: 23928022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin treatment in Gram-positive vascular graft infections.
    Arnaiz de Las Revillas F; Fernandez-Sampedro M; Arnaiz-García AM; Gutierrez-Cuadra M; Armiñanzas C; Pulitani I; Ponton A; Tascon V; García I; Fariñas MC
    Int J Infect Dis; 2018 Mar; 68():69-73. PubMed ID: 29373845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight
    Fox AN; Smith WJ; Kupiec KE; Harding SJ; Resman-Targoff BH; Neely SB; White BP; Owens RE
    Ther Adv Infect Dis; 2019; 6():2049936118820230. PubMed ID: 30728962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.